Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

(2011) C. Lieu et al.   CLINICAL CANCER RESEARCH

Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma

(2011) Bernard Escudier et al.   DRUGS

Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab

(2011) Camillo Porta et al.   Immunotherapy

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

(2011) James Finke et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

(2010) J-F Rossi et al.   BRITISH JOURNAL OF CANCER

Signaling pathways in renal cell carcinoma

(2010) Gowrishankar Banumathy et al.   CANCER BIOLOGY & THERAPY

Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

(2010) D. Huang et al.   CANCER RESEARCH

VHL and HIF signalling in renal cell carcinogenesis

(2010) Marcella M Baldewijns et al.   JOURNAL OF PATHOLOGY

Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study

(2010) H. J. Hammers et al.   MOLECULAR CANCER THERAPEUTICS

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib

(2010) J C Welti et al.   ONCOGENE

Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

(2009) Scott Kopetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

(2008) D. Sarker et al.   CLINICAL CANCER RESEARCH